Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of Antithrombin-Modulating Genes. Role of LARGE, a Gene Encoding a Bifunctional Glycosyltransferase, in the Secretion of Proteins?

  • de la Morena-Barrio, María Eugenia
  • Buil, Alfonso|||0000-0002-3097-1014
  • Antón, Ana Isabel
  • Martínez-Martínez, Irene
  • Miñano, Antonia
  • Gutiérrez-Gallego, Ricardo
  • Navarro-Fernández, José
  • Aguila, Sonia
  • Souto, Juan Carlos|||0000-0003-2092-5142
  • Vicente, Vicente
  • Soria Fernández, José Manuel|||0000-0002-6226-4293
  • Corral de la Calle, Javier
The haemostatic relevance of antithrombin together with the low genetic variability of SERPINC1, and the high heritability of plasma levels encourage the search for modulating genes. We used a hypothesis-free approach to identify these genes, evaluating associations between plasma antithrombin and 307,984 polymorphisms in the GAIT study (352 individuals from 21 Spanish families). Despite no SNP reaching the genome wide significance threshold, we verified milder positive associations in 307 blood donors from a different cohort. This validation study suggested LARGE, a gene encoding a protein with xylosyltransferase and glucuronyltransferase activities that forms heparin-like linear polysaccharides, as a potential modulator of antithrombin based on the significant association of one SNPs, rs762057, with anti-FXa activity, particularly after adjustment for age, sex and SERPINC1 rs2227589 genotype, all factors influencing antithrombin levels (p = 0.02). Additional results sustained this association. LARGE silencing inHepG2 and HEK-EBNA cells did not affect SERPINC1 mRNA levels but significantly reduced the secretion of antithrombin with moderate intracellular retention. Milder effects were observed on α1-antitrypsin, prothrombin and transferrin. Our study suggests LARGE as the first known modifier of plasma antithrombin, and proposes a new role for LARGE in modulating extracellular secretion of certain glycoproteins. © 2013 de la Morena-Barrio et al.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex-specific regulation of mitochondrial DNA levels, Genome-wide linkage analysis to identify quantitative trait loci

  • López, Sonia|||0000-0002-5023-5153
  • Buil, Alfonso|||0000-0002-3097-1014
  • Souto, Juan Carlos|||0000-0003-2092-5142
  • Casademont i Pou, Jordi|||0000-0002-8100-1827
  • Blangero, John
  • Martinez-Perez, Angel|||0000-0002-5934-1454
  • Fontcuberta, Jordi
  • Lathrop, Mark
  • Almasy, Laura
  • Soria Fernández, José Manuel|||0000-0002-6226-4293
Altered mitochondrial DNA (mtDNA) levels have been associated with common diseases in humans. We investigated the genetic mechanism that controls mtDNA levels using genome-wide linkage analyses in families from the Genetic Analysis of Idiopathic Thrombophilia Project (GAIT). We measure mtDNA levels by quantitative real-time PCR in 386 subjects from 21 extended Spanish families. A variance component linkage method using 485 microsatellites was conducted to evaluate linkage and to detect quantitative trait loci (QTLs) involved in the control of mtDNA levels. The heritalibility of mtDNA levels was 0.33 (p = 1.82e-05). We identified a QTL on Chromosome 2 (LOD = 2.21) using all of the subjects, independently on their sex. When females and males were analysed separately, three QTLs were identified. Females showed the same QTL on Chromosome 2 (LOD = 3.09), indicating that the QTL identified in the analysis using all of the subjects was a strong female QTL, and another one on Chromosome 3 (LOD = 2.67), whereas in males a QTL was identified on Chromosome 1 (LOD = 2.81). These QTLs were fine-mapped to find associations with mtDNA levels. The most significant SNP association was for the rs10888838 on Chromosome 1 in males. This SNP mapped to the gene MRPL37, involved in mitochondrial protein translation. The rs2140855 on Chromosome 2 showed association in the analysis using all of the subjects. It was near the gene CMPK2, which encodes a mitochondrial enzyme of the salvage pathway of deoxyribonucleotide synthesis. Our results provide evidence of a sex-specific genetic mechanism for the control of mtDNA levels and provide a framework to identify new genes that influence mtDNA levels. © 2012 López et al.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps

  • Segarra Casas, Alba|||0000-0001-5185-5031
  • Iruzubieta, Pablo
  • Kapetanovic, Solange
  • Hernández-Laín, Aurelio
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Fernández-Torrón, Roberto
  • Maneiro, Miren
  • Marco-Moreno, Pablo|||0000-0002-0302-9031
  • Zelaya-Huerta, M. Victoria
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Calafell, Francesc|||0000-0002-1083-9438
  • Töpf, Ana
  • Straub, Volker|||0000-0001-9046-3540
  • Vallejo-Illarramendi, Ainara
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • Gallano, Pia|||0000-0001-8104-2197
  • González Quereda, Lidia|||0000-0003-0715-6414
Background and purpose: Pathogenic variants in the RYR1 gene have been associated with a variety of conditions, ranging from congenital myopathy to adult manifestations. Our aim was to characterize the p.Leu2286Val variant in 17 Basque patients, to accurately determine its correlation with clinical features and to explore the possible founder effect of the variant. Methods: Families harbouring the p.Leu2286 RYR1 variant underwent a detailed clinical evaluation, including muscle magnetic resonance imaging, electromyography and muscle biopsy. Haplotypes were analysed in available patients and their relatives. Results: Individuals carrying the p.Leu2286Val shared a common haplotype, suggesting a founder event in the Basque Country population. The most prevalent features were exertional myalgia, high creatine kinase (CK) levels, cramps and muscle hypertrophy. None of the patients carrying only the p.Leu2286Val showed progression to severe muscle weakness and muscle magnetic resonance imaging showed a heterogeneous muscle involvement. Muscle biopsy revealed non-specific findings in two patients and features associated with central core disease in one patient carrying only the p.Leu2286Val and two patients harbouring an additional RYR1 variant. Three individuals carrying an in trans RYR1 variant presented with an earlier onset and more severe phenotype. Conclusion: Here, it is shown that the dominantly inherited p.Leu2286Val RYR1 founder variant is associated with a milder phenotype of exercise intolerance, myalgia and hyperCKemia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Translating Muscle RNAseq Into the Clinic for the Diagnosis of Muscle Diseases

  • Segarra Casas, Alba|||0000-0001-5185-5031
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Natera-de Benito, Daniel|||0000-0001-7764-2085
  • Kapetanovic, Solange
  • Hernández-Laín, Aurelio
  • Estévez-Arias, Berta|||0000-0002-1711-7489
  • Llansó, Laura|||0000-0003-4950-7657
  • Ortez, Carlos
  • Jou, Cristina|||0000-0002-2223-7880
  • Martí-Carrera, Itxaso
  • López-Márquez, Arístides
  • Rodríguez, Maria José
  • González Mera, Laura
  • Nedkova, Velina
  • Fernández-Torrón, Roberto
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Juntas Morales, Raúl|||0000-0003-2205-1741
  • López-de Munain, Adolfo
  • Surralles, Jordi|||0000-0002-4041-7519
  • Nascimento, Andrés
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Gallano, Pia|||0000-0001-8104-2197
  • González Quereda, Lidia|||0000-0003-0715-6414
Objective: Approximately half of patients with hereditary myopathies remain without a definitive genetic diagnosis after DNA next-generation sequencing (NGS). Here, we implemented transcriptome analysis of muscle biopsies as a complementary diagnostic tool for patients with muscle disease but no definitive genetic diagnosis after exome sequencing. Methods: In total, 70 undiagnosed cases with suspected genetic muscular dystrophies or congenital myopathies were included in the study. Muscle RNAseq comprised the analysis of aberrant splicing, aberrant expression, and monoallelic expression. In addition, existing NGS data or variant calling from RNAseq were reanalyzed, and genome sequencing was performed in selected cases. Four aberrant splicing open-source tools were compared and assessed. Results: RNAseq established a diagnosis in 10/70 patients (14.3%) by identifying aberrant transcripts produced by single nucleotide variants (7/10) or copy number variants (3/10). Reanalysis of NGS data allowed the diagnosis in 9/70 individuals (12.9%). Based on this cohort, FRASER was the tool that reported more splicing outlier events per sample while showing the highest accuracy (81.26%). Conclusions: We demonstrate the utility of RNAseq in identifying causative variants in muscle diseases. Evaluation of four aberrant splicing tools allowed efficient identification of most pathogenic splicing events, obtaining a manageable number of candidate events for manual inspection, demonstrating feasibility for translation into a clinical setting. We also show how the integration of omic technologies reduces the turnaround time to identify causative variants.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Repeat Expansions in PLIN4 Cause Autosomal Dominant Vacuolar Myopathy With Sarcolemmal Features

  • Llansó, Laura|||0000-0003-4950-7657
  • Stevanovski, Igor
  • Morís, Germán|||0000-0001-7608-2194
  • Collet Vidiella, Roger|||0000-0003-1668-1018
  • Segarra Casas, Alba|||0000-0001-5185-5031
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Gallano, Pia|||0000-0001-8104-2197
  • Alvarez, Rodrigo
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Blanco, Rosa
  • San-Millán, Beatriz
  • Navarro, Carmen|||0000-0003-4445-8585
  • Illa, Isabel|||0000-0002-2186-2684
  • Ravenscroft, Gianina|||0000-0003-3634-211X
  • W. Deveson, Ira
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
Objective: We aim to describe and characterize two unrelated Spanish families suffering from an autosomal dominant autophagic vacuolar myopathy caused by repeat expansions in PLIN4. Methods: We evaluated the clinical phenotype and muscle imaging, and performed a genetic workup that included exome sequencing, muscle RNAseq, and long-read genome sequencing. Muscle pathology was assessed by means of histochemistry, electron microscopy, PLIN4, p62, LC3, and NBR1 immunofluorescence and/or western blotting. Detailed characterization of autophagic vacuoles was performed. Results: Patients presented around the age of 30 with mild proximal weakness followed by prominent distal weakness in lower legs, eventually spreading to other muscle groups. Muscle biopsies showed unique pathological features characterized by numerous rimmed vacuoles that displayed sarcolemmal features and were located beneath the sarcolemma and within the cytoplasm. Ultrastructural studies showed autophagic vacuoles, replications, and loops of the basal lamina and tubulofilamentous sarcoplasmic inclusions. p62 and NBR1 co-localized with PLIN4 at the sarcolemma and vacuoles. LC3 immunoreactivity and other lysosomal markers were increased at the vacuoles. Targeted long-read sequencing of PLIN4 in affected individuals revealed a single expanded allele of 39 × 99 bp repeats in family 1 and of 37 × 99 bp repeats in family 2. Interpretation: We characterize two new families suffering from an autosomal dominant myopathy carrying repeat expansions in PLIN4. Subsarcolemmal p62 expression is a powerful although nonspecific marker of this disease. No correlation between the size of the expansion and clinical severity can be clearly established. PLIN4 expansions should be considered in the diagnosis of autosomal dominant vacuolar myopathies, especially when sarcolemmal features are present.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Identification of antithrombin-modulating genes. Role of LARGE, a gene encoding a bifunctional

  • de la Morena-Barrio, María Eugenia
  • Buil, Alfonso
  • Antón, Ana Isabel
  • Martínez-Martínez, Irene
  • Miñano, Antornia
  • Gutiérrez Gallego, Ricardo, 1968-
  • Navarro-Fernández, José
  • Águila, Sonia
  • Souto, Juan Carlos
  • Vicente, Vicente
  • Soria, José Manuel
  • Corral, Javier
The haemostatic relevance of antithrombin together with the low genetic variability of SERPINC1, and the high heritability of plasma levels encourage the search for modulating genes. We used a hypothesis-free approach to identify these genes, evaluating associations between plasma antithrombin and 307,984 polymorphisms in the GAIT study (352 individuals from 21 Spanish families). Despite no SNP reaching the genome wide significance threshold, we verified milder positive associations in 307 blood donors from a different cohort. This validation study suggested LARGE, a gene encoding a protein with xylosyltransferase and glucuronyltransferase activities that forms heparin-like linear polysaccharides, as a potential modulator of antithrombin based on the significant association of one SNPs, rs762057, with anti-FXa activity, particularly after adjustment for age, sex and SERPINC1 rs2227589 genotype, all factors influencing antithrombin levels (p = 0.02). Additional results sustained this association. LARGE silencing inHepG2 and HEK-EBNA cells did not affect SERPINC1 mRNA levels but significantly reduced the secretion of antithrombin with moderate intracellular retention. Milder effects were observed on α1-antitrypsin, prothrombin and transferrin. Our study suggests LARGE as the first known modifier of plasma antithrombin, and proposes a new role for LARGE in modulating extracellular secretion of certain glycoproteins, This study was supported partially by 04515/GERM/06 (Fundación Séneca de la Región de Murcia), SAF2009-08993 and SAF2008/01859 (Spanish Ministerio de Ciencia y Tecnología & Fondo Europeo de Desarrollo Regional de la Unión Europea FEDER), PI-08/0756, PI-11/0184 and RECAVA RD06/0014/0039 & RD06/0014/0016 (Spanish Instituto de Salud Carlos III & Fondo Europeo de Desarrollo Regional de la Unión Europea FEDER), and Centre National du Genotypage (Evry, France). MEMB is a holder of a predoctoral research grant from Spanish Instituto de Salud Carlos III (FI09/00190). IMM is a researcher from Fundació n para la Formación e Investigación Sanitarias. JNF is a postdoctoral researcher of the University of Murcia. JM Soria was supported by ‘‘Programa d’ Estabilització d’Investigadors de la Direcció d’Estrategia i Coordinació del Departament de Salut’’ (Generalitat de Catalunya).
Repisalud
Publication Artículo científico (JournalArticle)

Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming

  • Sánchez-Paulete, Alfonso R
  • Teijeira, Álvaro
  • Quetglas, José I
  • Rodríguez-Ruiz, María E
  • Sánchez-Arráez, Álvaro
  • Labiano, Sara
  • Etxeberria, Iñaki
  • Azpilikueta, Arantza
  • Bolaños, Elixabet
  • Ballesteros-Briones, María Cristina
  • Casares, Noelia
  • Quezada, Sergio A
  • Berraondo, Pedro
  • Sancho, David
  • Smerdou, Cristian
  • Melero, Ignacio
: Multiple lines of evidence indicate a critical role of antigen cross-presentation by conventional BATF3-dependent type 1 classical dendritic cells (cDC1) in CD8-mediated antitumor immunity. Flt3L and XCL1, respectively, constitute a key growth/differentiation factor and a potent and specific chemoattractant for cDC1. To exploit their antitumor functions in local immunotherapy, we prepared Semliki Forest Virus (SFV)-based vectors encoding XCL1 and soluble Flt3L (sFlt3L). These vectors readily conferred transgene expression to the tumor cells in culture and when engrafted as subcutaneous mouse tumor models. In syngeneic mice, intratumoral injection of SFV-XCL1-sFlt3L (SFV-XF) delayed progression of MC38- and B16-derived tumors. Therapeutic activity was observed and exerted additive effects in combination with anti-PD-1, anti-CD137, or CTLA-4 immunostimulatory mAbs. Therapeutic effects were abolished by CD8β T-cell depletion and were enhanced by CD4 T-cell depletion, but not by T regulatory cell predepletion with anti-CD25 mAb. Antitumor effects were also abolished in BATF3- and IFNAR-deficient mice. In B16-OVA tumors, SFV-XF increased the number of infiltrating CD8 T cells, including those recognizing OVA. Consistently, following the intratumoral SFV-XF treatment courses, we observed increased BATF3-dependent cDC1 among B16-OVA tumor-infiltrating leukocytes. Such an intratumoral increase was not seen in MC38-derived tumors, but both resident and migratory cDC1 were boosted in SFV-XF-treated MC38 tumor-draining lymph nodes. In conclusion, viral gene transfer of sFlt3L and XCL1 is feasible, safe, and biologically active in mice, exerting antitumor effects that can be potentiated by CD4 T-cell depletion. SIGNIFICANCE: These findings demonstrate that transgenic expression of sFLT3L and XCL1 in tumor cells mediates cross-priming of, and elicits potent antitumor activity from, CD8 T lymphocytes, particularly in combination with CD4 T-cell depletion.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Influence of film thickness and substrate roughness on the formation of laser induced periodic surface structures in poly(ethylene terephthalate) films deposited over gold substrates

  • Prada-Rodrigo, Javier
  • Rodríguez-Beltrán, René I.
  • Ezquerra, Tiberio A.
  • Moreno, Pablo
  • Rebollar, Esther
10 pags., 10 figs., 4 tabs., A study of the formation of Laser Induced Periodic Surface Structures (LIPSS) using near-infrared femtosecond pulsed laser irradiation on poly(ethylene terephthalate) (PET) films deposited over gold substrates has been carried out. We report the influence of the gold substrate roughness and the PET film thickness on LIPSS formation and analyze it in terms of the features of the electric field distribution obtained by computer simulations using COMSOLTM. We obtain LIPSS with periods close to the irradiation wavelength as long as the aforementioned substrate and film parameters remain below certain threshold values, in particular for polymer thicknesses below 200 nm and substrate roughness of few nm. However, experiments show the impossibility of LIPSS formation for rough substrates as well as thick films above these threshold values. In our numerical simulations, we notice the generation of Surface Plasmon Polariton (SPP) in the film-substrate interface that gives rise to a periodical field pattern on the surface of the thin film. This periodicity is broken for a certain level of substrate roughness or film thickness. Moreover, the evolution of the period of the SPP as the substrate roughness and film thickness change for given laser parameters is qualitatively in good agreement with the experimental LIPSS period (below but close to the irradiation laser wavelength). In conclusion, the experimental findings are explained by the formation and behavior of SPP in the thin film-substrate interface. On these grounds, we propose that, for our case of study, this SPP formation and the subsequent inhomogeneous rise in temperature induced by the periodic field on the surface of the sample is the leading mechanism contributing to LIPSS formation., Funding: This work was supported by the Spanish State Research Agency (AEI), Spain [project numbers PID2020-119003GB-I00/MCIN/AEI/10.13039/501100011033, PID2019-107514GB-I00/AEI/10.13039/501100011033, and PID2019-106125GB-I00/AEI/10.13039/501100011033] and the Junta de Castilla y León, Spain [project number SA136P20]. J.P.-R. thanks the Spanish Ministry of Universities, Spain [grant number FPU17/01859]., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of antithrombin-modulating genes. Role of LARGE, a gene encoding a bifunctional

  • de la Morena-Barrio, María Eugenia
  • Buil, Alfonso
  • Antón, Ana Isabel
  • Martínez-Martínez, Irene
  • Miñano, Antornia
  • Gutiérrez Gallego, Ricardo, 1968-
  • Navarro-Fernández, José
  • Águila, Sonia
  • Souto, Juan Carlos
  • Vicente, Vicente
  • Soria, José Manuel
  • Corral, Javier
The haemostatic relevance of antithrombin together with the low genetic variability of SERPINC1, and the high heritability of plasma levels encourage the search for modulating genes. We used a hypothesis-free approach to identify these genes, evaluating associations between plasma antithrombin and 307,984 polymorphisms in the GAIT study (352 individuals from 21 Spanish families). Despite no SNP reaching the genome wide significance threshold, we verified milder positive associations in 307 blood donors from a different cohort. This validation study suggested LARGE, a gene encoding a protein with xylosyltransferase and glucuronyltransferase activities that forms heparin-like linear polysaccharides, as a potential modulator of antithrombin based on the significant association of one SNPs, rs762057, with anti-FXa activity, particularly after adjustment for age, sex and SERPINC1 rs2227589 genotype, all factors influencing antithrombin levels (p = 0.02). Additional results sustained this association. LARGE silencing inHepG2 and HEK-EBNA cells did not affect SERPINC1 mRNA levels but significantly reduced the secretion of antithrombin with moderate intracellular retention. Milder effects were observed on α1-antitrypsin, prothrombin and transferrin. Our study suggests LARGE as the first known modifier of plasma antithrombin, and proposes a new role for LARGE in modulating extracellular secretion of certain glycoproteins, This study was supported partially by 04515/GERM/06 (Fundación Séneca de la Región de Murcia), SAF2009-08993 and SAF2008/01859 (Spanish Ministerio de Ciencia y Tecnología & Fondo Europeo de Desarrollo Regional de la Unión Europea FEDER), PI-08/0756, PI-11/0184 and RECAVA RD06/0014/0039 & RD06/0014/0016 (Spanish Instituto de Salud Carlos III & Fondo Europeo de Desarrollo Regional de la Unión Europea FEDER), and Centre National du Genotypage (Evry, France). MEMB is a holder of a predoctoral research grant from Spanish Instituto de Salud Carlos III (FI09/00190). IMM is a researcher from Fundació n para la Formación e Investigación Sanitarias. JNF is a postdoctoral researcher of the University of Murcia. JM Soria was supported by ‘‘Programa d’ Estabilització d’Investigadors de la Direcció d’Estrategia i Coordinació del Departament de Salut’’ (Generalitat de Catalunya).